Illumina selected to help bring precision medicine into everyday healthcare in Singapore

SG-INSIGHT marks a planned shift from studying mainly healthy volunteers to people with a broad range of medical conditions.

Rhea-AI Summary

Illumina (Nasdaq: ILMN) has been selected to provide whole-genome sequencing services for Singapore's SG-INSIGHT precision medicine study. The study, part of Phase III of the National Precision Medicine programme, is expected to include around 450,000 individuals, or approximately one in 10 Singapore residents. It aims to connect genomic and health data to inform preventive care and the responsible introduction of genetic screening in public healthcare.

Illumina won the assignment through an international competitive tender and will perform sequencing at its local genomics facility. The facility will seek the necessary accreditation. The selection follows Illumina's support for Phase II, which covered more than 100,000 genomes from healthy volunteers.

1 point · 0 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 1 point

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate point. Forward-looking: it has not happened yet and may not happen.SG-INSIGHT selection adds sequencing work for a study expected to include around 450,000 individuals.

Negative

• Minor pointNecessary accreditation remains to be sought for the Singapore genomics facility performing the sequencing.

Key Figures

Study population: Approximately 450,000 individuals Genomes covered: More than 100,000 genomes

Study population

Approximately 450,000 individuals

SG-INSIGHT study; around 1 in 10 Singapore residents

Genomes covered

More than 100,000 genomes

Prior NPM Phase II, PRECISE-SG100K

Key Terms

whole-genome sequencing, bioinformatics

2 terms

whole-genome sequencing technical

"provide whole-genome sequencing services for the SG-INSIGHT study"

Whole-genome sequencing is the process of reading an organism’s entire DNA instruction manual to capture all genetic information rather than just selected parts. For investors, it matters because having the full genetic picture can reveal new diagnostics, drug targets, or personalized treatments that drive product value, regulatory approvals, and long-term revenue potential, while improvements in speed and cost can expand market reach like making a complex map easier and cheaper to produce.

bioinformatics technical

"scientific, laboratory and bioinformatics teams will oversee sample preparation"

The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system

SINGAPORE, Nov. 2, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) programme. Expected to include approximately one in 10 Singapore residents, or around 450,000 individuals, the study is designed to generate evidence from genomic and health data to help inform preventive approaches to healthcare.

The study marks an important and planned transition from studying genomics primarily in healthy volunteers to studying those with a broad range of medical conditions. By connecting genomic information with real-world health data, SG-INSIGHT aims to better understand disease and treatment responses, support the responsible introduction of genetic screening in Singapore's public healthcare system, and help healthcare become more tailored to individuals over time.

"Singapore is showing what the future of precision medicine can look like at national scale," said Jacob Thaysen, Chief Executive Officer of Illumina. "By bringing genomic information closer to everyday healthcare, this programme has the potential to advance understanding of disease, generate evidence that support more informed care decisions, and ultimately move healthcare toward earlier, more precise intervention. We are proud to bring Illumina's technology, expertise and longstanding presence in Singapore to help make that vision possible."

"Phase III builds on nearly a decade of precision medicine in Singapore," said Professor Patrick Tan, Executive Director of PRECISE. "By extending the programme to patients across the public healthcare system, SG-INSIGHT aims to deepen understanding of how genetic, lifestyle and environmental factors are associated with health and disease. Phase III reflects Singapore's ambition to build a trusted and sustainable precision health ecosystem grounded in the needs and diversity of its population."

Illumina will perform the sequencing in Singapore through its local genomics facility where scientific, laboratory and bioinformatics teams will oversee sample preparation, sequencing, and genomic data analysis. Co-located with Illumina's manufacturing and R&D operations, the facility will seek the necessary accreditation and comply with Singapore's Healthcare Services Act 2020 (HCSA), strengthening its commitment to quality, safety, regulatory compliance and biomedical innovation. 

Illumina's selection for the SG-INSIGHT Study was awarded through an international competitive tender. It builds on an existing multi-year engagement, through which Illumina supported the successful implementation and delivery of NPM Phase II, PRECISE-SG100K, covering more than 100,000 genomes from healthy volunteers.

"For nearly two decades, Singapore has been one of Illumina's most important centres for innovation, manufacturing and talent in Asia Pacific," said Nilesh Shah, Head of Region, Asia Pacific, Illumina. "Our long-standing relationship with PRECISE represents the next chapter in that commitment - combining Singapore's leadership in precision health with Illumina's local genomic capabilities and regional expertise. We remain committed to investing in the people, technology and partnerships that can help advance genomics responsibly in Singapore and across the region."

Illumina established its presence in Singapore in 2008. Today, Singapore serves as the company's Asia Pacific regional headquarters and one of its largest hubs outside the United States, with more than 1,700 employees across three locations.  Illumina operations in Singapore encompass commercial operations, manufacturing, and R&D, supporting global research and innovation across sequencing platforms, software, and emerging technologies.

About PRECISE

Precision Health Research, Singapore (PRECISE) is the national central entity coordinating Singapore's multi-phase National Precision Medicine (NPM) programme. Established to drive a whole-of-Singapore effort, PRECISE works with research, clinical and industry partners to generate insights into Asian genomics and translate these into better health outcomes and economic opportunities.

PRECISE is a programme of the Consortium for Clinical Research and Innovation, Singapore. NPM Phase II is supported by the National Research Foundation, Singapore (NRF) under the White Space funding (MOH-000588 and MOH-001264) and administered by the Singapore Ministry of Health (MOH) through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd. NPM Phase III is supported by the Singapore MOH through the NMRC Office, MOH Holdings Pte Ltd under the NMRC NPM Phase III Funding Initiative (MOH-001734).

https://www.npm.sg/

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts
Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

View original content:https://www.prnewswire.com/news-releases/illumina-selected-to-help-bring-precision-medicine-into-everyday-healthcare-in-singapore-302927093.html

SOURCE Illumina, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Illumina do for Singapore's SG-INSIGHT study?

Illumina will provide whole-genome sequencing services for SG-INSIGHT through its Singapore genomics facility. The study is expected to include around 450,000 individuals and aims to connect genomic information with health data to inform preventive healthcare.

Which stages of SG-INSIGHT sequencing will Illumina's Singapore teams oversee?

Illumina's Singapore scientific, laboratory and bioinformatics teams will oversee sample preparation, sequencing, and genomic data analysis. The work will take place at its local genomics facility, co-located with its manufacturing and research and development operations.